NXTC NextCure Inc: Enterprise Value-to-Revenue Multiple

Public company logo of nextcure.com (NXTC)

Risks for NextCure, Inc. (NXTC) are linked to fierce competition in early-stage immuno-oncology. On GURU.Markets, current EV/Sales price action has identified a support level where the value stabilized at 0.00. Stability is underpinned by low antibody production costs during scaling and the diversification of treatment approaches for various types of cancer to combat therapy resistance.

Company Value to Revenue: NextCure Inc (NXTC) for 11/23/2025 - 11/20/2026

nextcure.com - analytical breakdowns and key metrics (NXTC)

- share price and consensus valuation forecast:
Initial company analysis:NextCure, Inc. NXTC
Product sample of NextCure, Inc.

Professional managers utilize fundamental filters to separate overvalued assets from undervalued ones by analyzing business value relative to net debt to sales. In the case of NextCure, Inc. (NXTC), the EV/Sales multiple trend reflects market expectations for the scaling of its immuno-oncology portfolio, allowing for an assessment of whether the current capitalization is justified by the potential of new antibodies to combat tumor resistance.

Competitor analysis for NextCure, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP